As of 2026-03-25, the Relative Valuation of Summit Therapeutics Inc (SMMT) is (19.58) USD. This relative valuation is based on P/E multiples. With the latest stock price at 15.54 USD, the upside of Summit Therapeutics Inc based on Relative Valuation is -226.0%.
The range of the Relative Valuation is (17.78) - (20.57) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 18.5x - 22.7x | 20.1x |
| Forward P/E multiples | 17.7x - 21.4x | 20.6x |
| Fair Price | (17.78) - (20.57) | (19.58) |
| Upside | -214.4% - -232.4% | -226.0% |
| Date | P/E |
| 2026-03-20 | -16.12 |
| 2026-03-19 | -16.34 |
| 2026-03-18 | -16.21 |
| 2026-03-17 | -16.47 |
| 2026-03-16 | -16.81 |
| 2026-03-13 | -16.75 |
| 2026-03-12 | -16.07 |
| 2026-03-11 | -16.71 |
| 2026-03-10 | -16.97 |
| 2026-03-09 | -16.34 |
| 2026-03-06 | -15.70 |
| 2026-03-05 | -15.53 |
| 2026-03-04 | -15.98 |
| 2026-03-03 | -15.70 |
| 2026-03-02 | -16.83 |
| 2026-02-27 | -17.24 |
| 2026-02-26 | -16.42 |
| 2026-02-25 | -16.30 |
| 2026-02-24 | -16.75 |
| 2026-02-23 | -16.72 |
| 2026-02-20 | -16.57 |
| 2026-02-19 | -16.49 |
| 2026-02-18 | -16.50 |
| 2026-02-17 | -16.30 |
| 2026-02-13 | -15.55 |
| 2026-02-12 | -15.20 |
| 2026-02-11 | -15.85 |
| 2026-02-10 | -15.85 |
| 2026-02-09 | -15.56 |
| 2026-02-06 | -15.58 |
| 2026-02-05 | -14.39 |
| 2026-02-04 | -14.99 |
| 2026-02-03 | -15.16 |
| 2026-02-02 | -14.61 |
| 2026-01-30 | -15.05 |
| 2026-01-29 | -16.00 |
| 2026-01-28 | -16.25 |
| 2026-01-27 | -16.52 |
| 2026-01-26 | -17.21 |
| 2026-01-23 | -17.14 |
| 2026-01-22 | -18.05 |
| 2026-01-21 | -17.51 |
| 2026-01-20 | -16.69 |
| 2026-01-16 | -17.71 |
| 2026-01-15 | -17.95 |
| 2026-01-14 | -18.34 |
| 2026-01-13 | -17.47 |
| 2026-01-12 | -17.71 |
| 2026-01-09 | -20.45 |
| 2026-01-08 | -19.57 |